Literature DB >> 21137037

Combining laser capture microdissection and proteomics: methodologies and clinical applications.

Baogang J Xu1.   

Abstract

Laser capture microdissection (LCM) has become an important tool for biomedical research. Various molecular biology techniques have been combined with LCM to reveal molecular profiles at an unprecedented tissue resolution. Proteomics is among those techniques that have proved fruitful in combination with LCM. This review provides an overview of the various proteomic techniques that have been developed for analyzing cells obtained using LCM. Methods for analyzing microdissected cells for various proteomic techniques are described and compared. In addition, various applications based on LCM and proteomics are discussed.
Copyright © 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Mesh：

Year:  2009        PMID： 21137037     DOI： 10.1002/prca.200900138

Source DB:  PubMed          Journal:  Proteomics Clin Appl        ISSN： 1862-8346            Impact factor:   3.494


  13 in total

1.  Protein analysis through Western blot of cells excised individually from human brain and muscle tissue.

Authors:  A O Koob; L Bruns; C Prassler; E Masliah; T Klopstock; A Bender
Journal:  Anal Biochem       Date:  2012-03-05       Impact factor: 3.365

2.  Spatial Quantification of Drugs in Pulmonary Tuberculosis Lesions by Laser Capture Microdissection Liquid Chromatography Mass Spectrometry (LCM-LC/MS).

Authors:  Matthew Zimmerman; Landry Blanc; Pei-Yu Chen; Véronique Dartois; Brendan Prideaux
Journal:  J Vis Exp       Date:  2018-04-18       Impact factor: 1.355

3.  The role of proteomics in assessing beta-cell dysfunction and death in type 1 diabetes.

Authors:  Ernesto S Nakayasu; Wei-Jun Qian; Carmella Evans-Molina; Raghavendra G Mirmira; Decio L Eizirik; Thomas O Metz
Journal:  Expert Rev Proteomics       Date:  2019-06-24       Impact factor: 3.940

4.  A quantitative proteomic workflow for characterization of frozen clinical biopsies: laser capture microdissection coupled with label-free mass spectrometry.

Authors:  John P Shapiro; Sabyasachi Biswas; Anand S Merchant; Anjali Satoskar; Cenny Taslim; Shili Lin; Brad H Rovin; Chandan K Sen; Sashwati Roy; Michael A Freitas
Journal:  J Proteomics       Date:  2012-09-25       Impact factor: 4.044

Review 5.  Reverse phase protein arrays: mapping the path towards personalized medicine.

Authors:  Rosa I Gallagher; Virginia Espina
Journal:  Mol Diagn Ther       Date:  2014-12       Impact factor: 4.074

6.  Proteomic Profiling in the Brain of CLN1 Disease Model Reveals Affected Functional Modules.

Authors:  Saara Tikka; Evanthia Monogioudi; Athanasios Gotsopoulos; Rabah Soliymani; Francesco Pezzini; Enzo Scifo; Kristiina Uusi-Rauva; Jaana Tyynelä; Marc Baumann; Anu Jalanko; Alessandro Simonati; Maciej Lalowski
Journal:  Neuromolecular Med       Date:  2015-12-26       Impact factor: 3.843

7.  A combined laser microdissection and mass spectrometry approach reveals new disease relevant proteins accumulating in aggregates of filaminopathy patients.

Authors:  Rudolf A Kley; Alexandra Maerkens; Yvonne Leber; Verena Theis; Anja Schreiner; Peter F M van der Ven; Julian Uszkoreit; Christian Stephan; Stefan Eulitz; Nicole Euler; Janbernd Kirschner; Klaus Müller; Helmut E Meyer; Martin Tegenthoff; Dieter O Fürst; Matthias Vorgerd; Thorsten Müller; Katrin Marcus
Journal:  Mol Cell Proteomics       Date:  2012-10-31       Impact factor: 5.911

Review 8.  Application of molecular technologies for phosphoproteomic analysis of clinical samples.

Authors:  M Pierobon; J Wulfkuhle; L Liotta; E Petricoin
Journal:  Oncogene       Date:  2014-03-10       Impact factor: 9.867

9.  Multimodal Imaging of Amyloid Plaques: Fusion of the Single-Probe Mass Spectrometry Image and Fluorescence Microscopy Image.

Authors:  Xiang Tian; Boer Xie; Zhu Zou; Yun Jiao; Li-En Lin; Chih-Lin Chen; Cheng-Chih Hsu; Junmin Peng; Zhibo Yang
Journal:  Anal Chem       Date:  2019-09-26       Impact factor: 8.008

10.  Label-free LC-MSe in tissue and serum reveals protein networks underlying differences between benign and malignant serous ovarian tumors.

Authors:  Wouter Wegdam; Carmen A Argmann; Gertjan Kramer; Johannes P Vissers; Marrije R Buist; Gemma G Kenter; Johannes M F G Aerts; Danielle Meijer; Perry D Moerland
Journal:  PLoS One       Date:  2014-09-29       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.